Us Bancorp \De\ Adma Biologics, Inc. Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 439 shares of ADMA stock, worth $7,441. This represents 0.0% of its overall portfolio holdings.

Number of Shares

439

Previous 421 4.28%

Holding current value

$7,441

Previous $8,000 12.5%

% of portfolio

0.0%

Previous 0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	BUY	$15.62 - $22.62 $281 - $407	18 Added 4.28%	439 $7,000
Q1 2024 May 07, 2024	BUY	$4.4 - $6.74 $1,852 - $2,837	421 New	421 $2,000
Q4 2022 Feb 13, 2023	BUY	$2.47 - $3.88 $708 - $1,113	287 New	287 $1,000
Q2 2021 Aug 05, 2021	SELL	$1.51 - $2.07 $44,924 - $61,584	-29,751 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$1.67 - $2.95 $49,684 - $87,765	29,751 New	29,751 $52,000
Q2 2020 Aug 07, 2020	SELL	$2.42 - $3.29 $2,441 - $3,319	-1,009 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$1.5 - $4.59 $1,513 - $4,631	1,009 New	1,009 $3,000

Others Institutions Holding ADMA

# of Institutions

322

Shares Held

190M

Call Options Held

917K

Put Options Held

91.6K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.33B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account